Introduction {#s1}
============

Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental toxicants found in air, water, plants, soil, and sediment in many countries. Occupational exposures to PAH are due to diesel exhaust, mining activities, and oil production. While genotoxic effects of PAHs have been extensively studied, diseases such as cancer are the consequence of reversible, non-genotoxic events, ie. tumor promotion as well as irreversible mutagenic events [@pone.0065150-Hazelton1]--[@pone.0065150-Trosko1]. High molecular weight (HMW) PAHs, such as benzo\[a\]pyrene (BaP), tend to elicit genotoxic effects while the lower molecular weight (LMW) PAHs have little to no observed carcinogenic initiation or genotoxic activity [@pone.0065150-ATSDR1]--[@pone.0065150-RoszinskyKocher1]. The two-four ring LMW PAHs are the most abundant PAHs in sidestream smoke or environmental tobacco smoke (ETS), reaching levels \>5,500 ng/cigarette, however, little is known about these PAHs and their potential as cancer promoters. While secondhand smoke exposure has greatly decreased in the U.S., except in apartment dwellings [@pone.0065150-Wilson1], other countries, such as China, Korea, Japan, India, Russia, Poland, and Egypt are still dealing with the effects of ETS, including childhood and adult asthma, chronic obstructive pulmonary disease (COPD), and cancer, as well as other associated etiologies such as reproductive health issues [@pone.0065150-Centers1]--[@pone.0065150-Miller1]. Both *in vivo* and *in vitro* evidence in several cell types suggests that these non-genotoxic PAHs can modulate mechanisms involved in pulmonary diseases, such as MAP kinases (MAPK), inflammatory signaling, and influence understudied signaling events such as gap junctional intercellular communication (GJIC) [@pone.0065150-Upham1], [@pone.0065150-Warshawsky1].

Alveolar type II pneumocyte is an epithelial cell type involved in many pulmonary diseases, such as asthma [@pone.0065150-Lloyd1] and COPD [@pone.0065150-Fujino1], and is a progenitor cell for lung adenocarcinoma (AC) in humans and mice, which is the most common type of lung cancer in both smokers and non-smokers [@pone.0065150-Schottenfeld1], [@pone.0065150-American1]. Non-tumorigenic C10 cells used in these studies were derived from type II cells in a BALB/c mouse and have been well characterized for basal and stimulated phenotypes [@pone.0065150-DwyerNield1]--[@pone.0065150-Thompson1], including contact growth inhibition.

Some of the mechanisms involved in pulmonary diseases, such as idiopathic pulmonary fibrosis (IPF) and cancer, include activation of mitogenic signal transduction pathways, dyregulation of GJIC [@pone.0065150-TrovatoSalinaro1], and induction of inflammation pathways [@pone.0065150-Hazelton1]--[@pone.0065150-Trosko1], [@pone.0065150-Bauer1]--[@pone.0065150-Rosenkranz1], which likely interact to elicit the observed effects (eg. promotion of initiated cells during carcinogenesis). Gap junctions, composed of connexins, are intercellular channels that allow for molecular communication between neighboring cells that are often inhibited by tumor promoters [@pone.0065150-Trosko1], however very little is known about their function in other pulmonary diseases. In a study that evaluated 251 chemicals, a stronger significant correlation was observed between tumorigenicity and GJIC than with that observed with mutagenicity, suggesting that GJIC is a valid marker for promotion [@pone.0065150-Rosenkranz1]. Tobacco smoke condensates and specific LMW PAHs in cigarettes, such as 1-Methylanthracene (1-MeA), as well as 12-O-tetradecanoylphorbol-13-acetate (TPA), a classic tumor promoter in several organs, have induced significant GJIC dysregulation in a liver cell line (WB-F44) [@pone.0065150-Upham2]--[@pone.0065150-Vang1]. Connexin 43 (Cx43) is the primary connexin expressed in alveolar type II and bronchiolar Clara cells [@pone.0065150-Guan1], [@pone.0065150-Johnson1], and its expression is significantly reduced in mouse C10 cells treated with the lung tumor promoter, butylated hydroxytoluene (BHT) [@pone.0065150-Guan1]. *Cx43^−/+^* mice also have significantly increased urethane-induced lung tumor susceptibility [@pone.0065150-Avanzo1], further suggesting a role for gap junctions in pulmonary carcinogenesis and other pulmonary diseases.

MAPK pathways are also activated in response to PAHs in liver and smooth muscle cells [@pone.0065150-Upham1], [@pone.0065150-Yan1]. In mouse alveolar type II cell lines (C10 and E10), ERK1/2 MAPK inhibition lead to decreased cell proliferation and in mouse lung, tumor regression and restored apoptosis [@pone.0065150-Rice1], [@pone.0065150-Ji1]. In addition, multiple *in vivo* and *in vitro* studies have linked inflammatory pathways upstream and downstream of MAPK with lung disease mechanisms for fibrosis [@pone.0065150-Walters1], COPD [@pone.0065150-Moghaddam1], and cancer (ie. tumor promotion) [@pone.0065150-Trosko1], [@pone.0065150-Bauer2], [@pone.0065150-Bernert1]--[@pone.0065150-Wattenberg1]. For example, Mcp-1(Ccl2), a known macrophage chemoattractant secreted in lungs by pulmonary epithelial cells, has been reported to affect MAPK activation [@pone.0065150-Rondini1].

The PAH isomers herein, 1- and 2-MeA, have been shown to have disparate effects on the dysregulation of GJIC, activation of MAPK and induction of arachidonic acid release in WB-F44 rat liver cells [@pone.0065150-Upham2]. The active GJIC inhibitor, 1-MeA, contains a bay-like structural region while the inactive isomer 2-MeA, does not ([Fig. 1](#pone-0065150-g001){ref-type="fig"}) [@pone.0065150-Upham2], [@pone.0065150-Blaha1], [@pone.0065150-Weis1]. These structural differences exist among other isomeric PAHs [@pone.0065150-Rummel1] and produced similar isomeric disparities in gap junction dysregulation as well as induction of apoptosis in a human monocyte cell line [@pone.0065150-Wan1]. We hypothesized that the active PAH (1-MeA) would also inhibit GJIC, activate MAPKs, and induce inflammatory cytokines and chemokines, in a mouse type II cell line in contrast to its isomer (2-MeA).

![Structures of 1- and 2-methylanthracene.\
An arrow indicates the bay-like region of 1-MeA.](pone.0065150.g001){#pone-0065150-g001}

Materials and Methods {#s2}
=====================

Materials and Reagents {#s2a}
----------------------

Reagents were purchased from Crescent Chemical (1-MeA; purity 99.5%) and Sigma Aldrich (St. Louis, MO; 2-MeA, purity 97%; acetonitrile, lucifer yellow, 12-O-tetradecanoylphorbol-13-acetate (TPA)). Stock solutions for PAHs and TPA were prepared by dissolving the compounds in acetonitrile or DMSO, respectively, which were also used as the vehicle controls. TEMED (USA) and acrylamide (China) were both purchased from BioRad (Hercules, CA). The p38 inhibitors (SB203580 and SB202190), ERK1/2 inhibitor (FR180204) and the MEK inhibitor (U0126) were purchased from Tocris Bioscience (Bristol, UK). All other reagents were purchased from Sigma Aldrich.

Cell Line Maintenance and Treatment with PAHs {#s2b}
---------------------------------------------

The C10 mouse cell line was obtained from Dr. Lori Dwyer Nield (University of Colorado, Aurora, CO) [@pone.0065150-Malkinson1]. C10 cells are cultured in CMRL 1066 (Gibco, Invitrogen, Grand Island, NY) with 10% FBS and 1% glutamate. Cells where grown in 35 mm tissue culture dishes for the scrape load-dye transfer (SL/DT) assays and 60 mm plates for the protein and RNA extractions in a humidified atmosphere at 37°C with 5% CO~2~ and 95% air. At confluence (2--3 days), serum deprivation was initiated for 24 h prior to experimental treatments. After serum deprivation, PAHs or vehicle (CH~3~CN) were applied directly to the plates without media change from a concentrated stock solution for all experiments.

Scrape-load/dye-transfer (SL/DT) Assay {#s2c}
--------------------------------------

The SL/DT assay was conducted following the method of Upham [@pone.0065150-Upham4]. Three cuts in the monolayer of cells were made with a steel scalpel in the presence of lucifer yellow (1 mg/ml of PBS) and allowed to transfer through the cells for three minutes. The cells were then fixed with 4% formalin and the dye spread was visualized with an Eclipse Ti-S microscope. Images were collected with a DS-QiMc camera (Nikon; Melville, NY) at a magnification of 100X. The images were quantified using ImageJ software (<http://imagej.nih.gov/ij/>) by measuring the area of dye spread of the PAH treated plates relative to the CH~3~CN vehicle. TPA was used as a positive control for all studies; the dose was determined in previous studies (50 nM, 60 min) [@pone.0065150-Chaudhuri1]. For the MAPK-inhibitor studies, U0126, SB203580, and SB202190 were applied separately 1 h prior to treatment with 1-MeA; doses used were previously published [@pone.0065150-Rice1], [@pone.0065150-Upham2], [@pone.0065150-Tong1]. Cytotoxicity assays were performed on confluent cells after 24 h serum deprivation followed by treatment with vehicle control or PAHs for 30 min, 1.5 h, and 6 h time points. The CellTiter 96 AQueous One Solution Cell Viability assay was then performed as described by the manufacturer and measured at 490 nm (MTS assay, Promega, Madison, WI).

Protein Extraction and Immunoblots {#s2d}
----------------------------------

Cells were exposed to PAH at set intervals of 15 min to 4 h, and then extracted with 20% SDS containing protease inhibitor (Protease Inhibitor Cocktail 100X, Sigma) and phosphatase inhibitor (Halt Phosphatase Inhibitor Cocktail 100X, Thermo Scientific). The BioRad DC protein assay was used to quantify protein. 15 µg of protein were separated on a 12.5% SDS page gel and transferred to polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA). Primary antibodies were incubated with the membranes overnight at 4°C, similar to Rondini et al. (2010) [@pone.0065150-Rondini1] : anti-mouse Cx43 from Millipore (monoclonal, 1∶7,500 dilution) and anti-rabbit from Cell Signaling for pP38, ERK1/2 and MAPKAPK-2 (1∶500 dilution, Cat\# 9215S), total P38 (1∶1,000 dilution, Cat\# 9212), pERK1/2 (1∶1,000, Cat\# 4370S), and total ERK1/2 (1∶1,000, Cat\#4695) pMAPKAPK-2 (1∶1,000, Cat\# 3007) and total MAPKAPK-2 (1∶1,000. Cat\# 3042). Secondary antibody conjugated with HRP was used (Pierce Goat anti-Rabbit for pP38, total P38, pERK1/2, and total ERK1/2 all at a dilution of 1∶7500 and for Cx43 goat anti mouse IgG-HRP from Santa Cruz at 1∶1000) and a tertiary antibody for pP38 with Streptavidin-HRP from ThermoScientific at 1∶25,000. Supersignal West Dura chemiluminescent detection was used for all proteins of interest. All immunoblots were quantified by densitometry using the BioRad Quantity One Software.

Immunostaining {#s2e}
--------------

Cells were grown on cover slips in a 12 well plate for 2 days and serum deprived for 24 hours before treatment. Following treatment, the cells were washed three times with PBS and fixed with warm 4% paraformaldehyde for 30 minutes. The cells were then washed again three times with PBS, permeabilized, and blocked with 5% BSA with 0.2% Triton X-100 in PBS for 90 minutes. After 90 minutes, primary antibody for Cx43 (Transduction Laboratories, monoclonal 1∶200, Cat\# C13720) was applied and incubated at 4° overnight. The following day the cells were washed with PBS and secondary antibody was applied for 90 minutes (Alexa Fluor 488 goat anti-mouse, monoclonal 1∶250, Invitrogen). The plate was again washed, coated with Prolong Gold antifade reagent containing DAPI (Invitrogen), allowed to dry overnight before it was sealed, and viewed on a confocal microscope (Nikon D-Eclipse C1, 1000X).

RNA Isolation and Quantitative Reverse Transcriptase-polymerase Chain Reaction (qRT-PCR) {#s2f}
----------------------------------------------------------------------------------------

RNA isolation was performed following the manufacturer's instructions using the Nucleospin RNA II kit (Macherey-Nagel, Duren, Germany). An aliquot (1 µg) of total lung RNA was reverse transcribed as previously published [@pone.0065150-Cho1], [@pone.0065150-Bauer3]. The cDNA was amplified in a 20 µl volume containing gene-specific primers labeled with SYBR Green master mix (Kappa Biosystems; Woburn, MA) using an Eppendorf Mastercycler ep Realplex (Eppendorf, Hauppauge, NY). *Ccl2* (*Mcp-1*) (For) 5′-GTCACCAAGCTCAAGAGAGA-3′, (Rev) 5′-GTCACTCCTACAG AAGTGCT-3; *Ptgs2 (Cox-2)*, (For) 5′-ATTGGTGGAGAGGTGTATCC-3′, (Rev) 5′-ACACTCTGTTGTGC TCCCGAA-3′; *Tnf* (For) 5′-ACGGCATGGATCTCAAAGAC-3′, *Tnf* (Rev) 5′-AGATAGCAAATCGGCTGACG-3′. The relative quantification of gene expression was calculated from the threshold cycle (C~T~) values for each sample and normalized in relation to the expression of 18S rRNA [@pone.0065150-Bauer4] using the comparative C~T~ method.

Statistical Analysis {#s2g}
--------------------

Data were expressed as the group mean ± standard error of the mean (SEM). Two-way ANOVA was used to evaluate the effects of treatment (vehicle, 1-MeA, 2-MeA) and concentration or time. The Student-Newman-Keuls test was used for *a posteriori* comparisons of means (*p*\<0.05). All of the statistical analyses were performed using SigmaStat 3.0 software program (SPSS Science Inc., Chicago, IL).

Results {#s3}
=======

GJIC in Response to LMW PAHs {#s3a}
----------------------------

Little cytotoxicity was observed in the C10 cells in response to either vehicle, 1- or 2-MeA treatments ([Fig. 2](#pone-0065150-g002){ref-type="fig"}) at doses between 25--150 µM for several time points (30 min, 1.5 and 6 h), thus all subsequent experiments on cell signaling were conducted at these non-cytotoxic doses and times. The CH~3~CN vehicle had no effect on GJIC and the positive control (TPA) demonstrated dysregulation of GJIC in C10 cells ([Fig. 3C](#pone-0065150-g003){ref-type="fig"}). 1-MeA was shown to inhibit GJIC in a concentration dependent manner in which the most significant change in the dysregulation of GJIC occurred between 10 and 25 µM with a maximum inhibition observed between 50--100 µM. Exposure to 2-MeA did not dysregulate GJIC, even at high concentrations ([Fig. 3A](#pone-0065150-g003){ref-type="fig"}). To assure robust responses for the other experiments, we chose a mid-value of 75 µM for maximum inhibition. Significant dose and treatment effects were observed for 1-MeA compared to the control or 2-MeA treatment (p\<0.05). A time course experiment indicated that 1-MeA significantly and rapidly inhibited GJIC, by 15 to 30 minutes, and continued to inhibit through the 6 h time point; while 2-MeA (200 µM) did not inhibit GJIC at any of the time points ([Fig. 3B](#pone-0065150-g003){ref-type="fig"}). [Figure 3D](#pone-0065150-g003){ref-type="fig"} depicts examples of the fluorescent images of the SL-DT assay lucifer yellow dye spread following treatment of the C10 cells with 1-MeA, 2-MeA, and TPA. Since 1-MeA was shown to inhibit GJIC quickly and effectively at a concentration of 75 µM, we investigated whether this effect was reversible after removal of 1-MeA and replacement with serum free media. Significant recovery of GJIC began after 30 min, however was not completely restored 4 h later ([Fig. 3E](#pone-0065150-g003){ref-type="fig"}).

![Cytotoxicity is not observed in response to 1 or 2-MeA in the C10 cells.\
The MTS assay observed no toxic levels of either PAH between 25--150 µM for 30 min, 1.5, or 6 h time points in the C10 cells. Mean ± SEM presented with n = 3 per study, replicated twice.](pone.0065150.g002){#pone-0065150-g002}

![Dose response, time course, and recovery studies following treatment with 1-and 2-MeA.\
(A) Dose response for 1 and 2-MeA from 0--200 µM. Acetonitrile (CH~3~CN) is the vehicle control for the PAHs for all studies. (B) Time course following treatment with 1 and 2-MeA from 0--4 h. 1-MeA (75 µM) and 2-MeA (200 µM). (C) TPA positive control (50 nM, 60 min) for GJIC dysregulation in C10 cells. DMSO is the vehicle control for the TPA. Mean ± SEM presented in A--C with n = 3 per study, replicated 3 times. 1-MeA, 1-methylanthracene; 2-MeA, 2-methylanthracene. ^\*^p\<0.05 compared to control; ^+^p\<0.05 compared to 2-MeA treated cells at the same concentration or time point. (D) Depiction of SL/DT assay after 30 min incubation with vehicle control (CH~3~CN), TPA (50 nM), 1-MeA, and 2-MeA treatment both at 75 µM demonstrating the lucifer yellow dye incorporation into the C10 cells that are communicating via gap junctions. DAPI was used for nuclear staining. Magnification at 100X. (E) Time to recovery for reversal of GJIC dysregulation in C10 cells following a 30 min treatment with 1-MeA. Black arrow indicates the removal of 1-MeA and replacement with serum-free media. Some recovery was observed approximately 1 h following removal of 1-MeA and continued through 4 h, although complete recovery was not seen. Mean ± SEM presented with n = 3 per study, replicated 3 times. ^\*^p\<0.05 compared to C10 cells at 0 time point which is 30 min following 1-MeA treatment.](pone.0065150.g003){#pone-0065150-g003}

MAP Kinase (MAPK) Activation {#s3b}
----------------------------

The activity of MAP kinase was assessed over a time course of 15 min to 4 h using immunoblotting techniques of the phosphorylated (activated) forms of ERK and p38 ([Fig. 4](#pone-0065150-g004){ref-type="fig"} and [5](#pone-0065150-g005){ref-type="fig"}). Phosphorylated ERK1/2 (pERK1/2) was significantly increased at 1--4 h by 1-MeA while 2-MeA and the vehicle control (Cntl) had no effect on the activation of pERK1/2 ([Fig. 4](#pone-0065150-g004){ref-type="fig"}). Phosphorylated P38 (pP38) also rapidly increased following exposure to 1-MeA, but not to exposure with 2-MeA or the vehicle ([Fig. 5](#pone-0065150-g005){ref-type="fig"}). The phosphorylation of P38 occurred within 15 min of exposure to 1-MeA, peaked at 1 h, and persisted through 4 h. Significant differences were observed for both pERK1/2 and pP38 after normalization to total ERK and total P38 in response to 1-MeA for both treatment and time, but not to 2-MeA or control treatments ([Fig. 4B](#pone-0065150-g004){ref-type="fig"} and [5B](#pone-0065150-g005){ref-type="fig"}). TPA was used as a positive control for pERK1/2 and pP38 in these studies, as observed in part C of [Figures 4](#pone-0065150-g004){ref-type="fig"} and [5](#pone-0065150-g005){ref-type="fig"}. Twenty-five and 50 µM doses of 1-MeA were also used to demonstrate increased activation of ERK1/2 at lower doses ([Fig. S1](#pone.0065150.s001){ref-type="supplementary-material"}).

![Phospho-ERK1/2 MAPK activation following treatment with 1- but not 2- MeA.\
(A) Immunoblot for pERK1/2 and total ERK for 15 min to 4 h of treatment. (B) Densitometric analysis of pERK1/2 normalized to total ERK, represented as percent control. Concentrations used: 75 µM 1-MeA and 75 µM 2-MeA. Mean ± SEM presented with n = 3 per study, replicated 3 times. 1-MeA, 1-methylanthracene; 2-MeA, 2-methylanthracene; Cntl, CH~3~CN vehicle control. ^\*^p\<0.05 compared to control; ^+^p\<0.05 compared to 2-MeA treated cells at the same time point. (C) Positive control using T, TPA (50 nM, 60 min) or D, DMSO (negative control) for activation of ERK1/2.](pone.0065150.g004){#pone-0065150-g004}

![PhosphopP38 (pP38) MAPK activation following treatment with 1- but not 2- MeA.\
(A) Immunoblot for pP38 and total p38 for 15 min to 4 h of treatment. (B) Densitometric analysis of pP38 normalized to total P38, represented as percent control. Concentrations used: 75 µM 1-MeA and 75 µM 2-MeA. Mean ± SEM presented with n = 3 per study, replicated 3 times. 1-MeA, 1-methylanthracene; 2-MeA, 2-methylanthracene; Cntl, CH~3~CN vehicle control. ^\*^p\<0.05 compared to control; ^+^p\<0.05 compared to 2-MeA treated cells at the same time point. (C) Positive control using T, TPA (50 nM, 60 min) or D, DMSO (negative control) for activation of P38.](pone.0065150.g005){#pone-0065150-g005}

Cx43 Expression {#s3c}
---------------

Immunoblot analyses were used to assess the relative protein levels and phosphorylation status of Cx43, the major gap junction protein of these pulmonary cells. The same time course was used for Cx43 as the MAPK (15 min--4 h). As observed with previous endpoints, CH~3~CN control had no effect on Cx43 protein expression levels, similar to the lack of effect on GJIC or MAPK activation ([Fig. 6](#pone-0065150-g006){ref-type="fig"}). There were no significant changes in the ratios of the three forms of Cx43 at 15 and 30 min, which indicate no change in phosphorylation of the connexins and are within the time period of 1-MeA-induced dysregulation of GJIC. However, 1-MeA did significantly reduce total Cx43 expression at the 2 and 4 h time points as compared to either the vehicle or 2-MeA exposure ([Fig. 6](#pone-0065150-g006){ref-type="fig"}). In contrast, TPA induced a hyperphosphorylation of the connexins as indicated by a mobility shift to higher molecular weights ([Fig. 6C](#pone-0065150-g006){ref-type="fig"}). This latter result indicated that Cx43 in lung cells are capable of phosphorylation changes, yet the 1-MeA had no effect on the phosphorylation status as determined by the lack of mobility shifts in immunoblots.

![Decreases in Cx43 protein expression following 1-MeA treatment but not 2-MeA treatment.\
(A) Immunoblot of Cx43 for 15 min to 4 h after treatment. (B) Densitometric analysis of Cx43 normalized to β-actin, represented as percent control. Concentrations used: 75 µM 1-MeA and 75 µM 2-MeA. Mean ± SEM presented with n = 3 per study, replicated 3 times. 1-MeA, 1-methylanthracene; 2-MeA, 2-methylanthracene; Cntl, CH~3~CN vehicle control. ^\*^p\<0.05 compared to control; ^+^p\<0.05 compared to 2-MeA treated cells at the same time point. (C) Positive control using T (TPA; 50 nM, 60 min) or D (DMSO; negative control) for activation of Cx43.](pone.0065150.g006){#pone-0065150-g006}

Cx43 immunostaining demonstrated punctate staining on the cell membrane in the vehicle or 2-MeA treated C10 cells at both 30 min and 4 h time points, however, in the 1-MeA exposed cells, the punctate staining decreased in the plasma membranes, became more apparent in the cytoplasm after 30 min, and almost completely disappeared by 4 h ([Fig. 7](#pone-0065150-g007){ref-type="fig"}). These events occurred after the dysregulation of GJIC and are similar to that observed with TPA in which dysfunctional GJIC lead to the connexins being retrafficked to the cytosolic cell compartments ([Fig. 7](#pone-0065150-g007){ref-type="fig"}).

![Reduced C10 cell Cx43 immunostaining in response to 1-MeA, but not 2-MeA treatment.\
Cells were treated with acetonitrile vehicle (CH~3~CN), 1-MeA (75 µM), 2-MeA (75 µM), TPA (50 nM, 60 min) as a positive control, and two negative controls, one without (w/o) primary antibody and one without (w/o) secondary antibody. Two time points were assessed, 30 min and 4 h to observe changes at several time points known to inhibit gap junctions. Magnification was at 1000X using a Nikon D-Eclipse C1 confocal microscope. Experiments were repeated twice.](pone.0065150.g007){#pone-0065150-g007}

Role of MAPK in the Dysregulation of GJIC {#s3d}
-----------------------------------------

Because the activation of P38 and ERK1/2 in response to 1-MeA occurred at time points when GJIC was also inhibited, we determined the effects of ERK1/2 and P38 dysregulation on GJIC activity. We pre-incubated the cells with either a MEK-inhibitor (U0126; inhibits upstream of ERK1/2), a specific ERK1/2 inhibitor (FR180204; inhibits ERK1 and 2) or a specific inhibitor of p38 (SB203580) and then assessed the effects of 1-MeA on GJIC. Inhibition of P38 prevented the dysregulation of GJIC by 1-MeA, while inhibition of the MEK pathway using U0126 and ERK1/2 using FR180204, had no effect on the dysregulation of GJIC elicited by 1-MeA ([Fig. 8](#pone-0065150-g008){ref-type="fig"}). An additional P38 inhibitor (SB202190, 20 µM, [@pone.0065150-Upham2]) was also used to reverse 1-MeA-induced dysregulation of GJIC and confirmed the SB203580 results (data not shown). Immunoblots of MAPKAPK-2, a known substrate for P38 [@pone.0065150-BenLevy1] were done to demonstrate inhibition of P38, since SB203580 inhibits p38 activity, but not necessarily phosphorylation [@pone.0065150-Tong1] (see [Fig. S2A](#pone.0065150.s002){ref-type="supplementary-material"}). pERK1/2 immunoblots also demonstrated inhibition of pERK with both U0126 and FR180204, although, FR180204 only partially inhibited ERK ([Fig. S2B](#pone.0065150.s002){ref-type="supplementary-material"}). These results indicate 1-MeA-induced dysregulation of GJIC depended, in part, on the p38, but not the ERK1/2 MAPK pathway. TPA-induced dysregulation of GJIC was prevented by U0126, the MEK inhibitor, which supports previous findings on the involvement of ERK1/2 MAPK in gap junction regulation with TPA [@pone.0065150-Ruch1].

![Reversal of 1-MeA-induced GJIC dysregulation using a p38 MAPK inhibitor.\
(A) U0126 (20 µM) and FR180204 (5 µM) were used to inhibit MEK or ERK1/2, respectively, prior to exposure to 1-MeA for 30 min. SL/DT assays were then done following 1-MeA treatment. TPA was also used as a positive control. Cntl, acetonitrile control; 1-MeA, 1-methylanthracene (75 µM, 30 min); U0126 alone (20 µM, 1 h prior); U0126+1-MeA, U0126 prior to incubation with 1-MeA; TPA (50 nM, 1 h), TPA alone; U0126+ TPA, U0126 prior to incubation with TPA; FR, FR180204 alone (5 µM, 1 h prior); FR +1-MeA, FR180204 prior to incubation with 1-MeA. Mean ± SEM presented with n = 3 per study, replicated 3 times. ^\*^p\<0.05 compared to control;^+^p\<0.05 compared to TPA treated cells. (B) SB203580 (2.5, 5 µM) was used to inhibit p38 1 h prior to exposure to 1-MeA for 30 min. SL/DT assays were then done following 1-MeA treatment. SB, SB203580 (2.5 or 5 µM, 1 h); SB +1-MeA, SB203580 prior to incubation with 1-MeA. ^\*^p\<0.05 compared to control; ^+^p\<0.05 compared to 1-MeA treated cells.](pone.0065150.g008){#pone-0065150-g008}

Inflammatory Pathways Downstream of MAPK {#s3e}
----------------------------------------

RNA expression for several pathways downstream of the MAPKs, among other pathways, was analyzed via qPCR for 2--6 h following 1- or 2-MeA treatments compared to vehicle treated cells at each time point ([Fig. 9](#pone-0065150-g009){ref-type="fig"}). *Ccl2* (*Mcp-1*; [Fig. 9A](#pone-0065150-g009){ref-type="fig"}) gene expression significantly increased at 4 h and was increased at 6 h following 1-MeA treatment, but was not observed in 2-MeA or vehicle treatments. *Cox2* (*Ptgs2;* [Fig. 9B](#pone-0065150-g009){ref-type="fig"}) expression was also highly elevated (between 18--80-fold; P\<0.05) at 2, 4 and 6 h time points compared to either 2-MeA or control treatments. *Cox-2* expression was slightly elevated at 2 h in the 2-MeA treatment group. *Tnf* ([Fig. 9](#pone-0065150-g009){ref-type="fig"} C) was also significantly elevated at 2 h in both 1- and 2-MeA compared to the vehicle treatment and remained significantly elevated only in the 1-MeA treatment at 4 h. However, by 6 h, repression of *Tnf* was observed in the 1- and 2-MeA treatment groups, suggesting feedback regulation of *Tnf* after the initial increase.

![Inflammatory pathways downstream of MAPKs and dysregulation of GJIC are influenced by 1-MeA.\
(A) *Ccl2*, or *Mcp-1*, mRNA expression in response to 1-MeA, 2-MeA, or control treated cells. (B) *Ptgs2*, or *Cox2*, mRNA expression in response to 1-MeA, 2-MeA, or control treated cells. (C) *Tnf* mRNA expression in response to 1-MeA, 2-MeA, or control treated cells. Concentrations used: 1-MeA, (75 µM) and 2-MeA (75 µM). For each gene, mean and SEM are presented; n = 3 per treatment, repeated twice. Genes are first normalized to 18S followed by normalization to acetonitrile control per time point. Cntl = control acetonitrile; 1-MeA, 1-methylanthracene; 2-MeA, 2-methlyanthracene; Ccl2, chemokine (CC-motif) ligand 2; Mcp-1, monocyte chemoattractant 2; Cox-2, cyclooxygenase 1; Ptgs2, prostaglandin-endoperoxide synthase 2; Tnf, tumor necrosis factor α.](pone.0065150.g009){#pone-0065150-g009}

Discussion {#s4}
==========

These novel studies address the effects of low molecular weight PAHs (1 and 2-MeA) on alveolar type II cells and identified several markers of downstream signaling pathways that were modulated in response to 1-MeA, but not 2-MeA. GJIC was dysregulated and MAPKs were activated (P38, pERK1/2) as an early response to the active PAH (1-MeA), but not to 2-MeA, suggesting a structure-activity relationship underlies the efficacy of responses. Longer-term effects included a decrease in the protein levels of Cx43, relocalization of Cx43 from the plasma membrane to the cytoplasm, and the induction of specific inflammatory mediators (*Mcp-1*, *Cox-2*, and *Tnf*). The rapid onset of GJIC dysregulation in our model at time points that coincide with observed increases in pP38 suggests an interaction between the MAPK pathways and regulation of gap junctions. Our finding that inhibition of P38 almost completely blocked the 1-MeA-induced dysregulation of gap junctions, indicates that the regulation of GJIC was, in fact, P38-dependent. In response to 1-MeA, the activation of pERK1/2 was subsequent (30 min) to the dysregulation of GJIC (\<15 min), and the inhibition of MEK or ERK1/2 with U0126 or FR180204, respectively, did not prevent the dysregulation of GJIC, which indicates that the ERK1/2 pathway was not involved in 1-MeA-induced dysregulation of GJIC. Cx43 protein levels decreased several hours after the dysregulation of GJIC, although the Cx43 staining at 30 min ([Fig. 7](#pone-0065150-g007){ref-type="fig"}) indicated early removal of Cx43 from the plasma membrane of treated cells, consistent with Cx43 trafficking. However, we cannot rule out the possibility that other connexins are involved in this 1-MeA-induced response. Alveolar type II cells can also express Cx26, Cx32, Cx37, and Cx46 and some can heterodimerize, although the concept of mixed gap junction channels remains controversial [@pone.0065150-Johnson1].

Gap Junctions and the Lung {#s4a}
--------------------------

Gap junctions have important roles in many normal physiological processes in the CNS, kidney, liver, heart, and lung, [@pone.0065150-Johnson1], [@pone.0065150-Eugenin1], [@pone.0065150-Sorensen1], and when channel resistance increases, impairment of function can lead to pathological states. In some lung diseases, such as acute lung injury, deficient communication between cells could be a causal mechanism. In lung fibroblasts isolated from idiopathic pulmonary fibrosis patients (IPF), gap junction activity and Cx43 expression was significantly decreased compared to controls [@pone.0065150-TrovatoSalinaro1], however the importance of decreased fibroblast communication in fibrosis is not clear.

Changes in the phosphorylation status of the connexin proteins have been implicated in the dysregulation of GJIC [@pone.0065150-Abdelmohsen1]--[@pone.0065150-Musil1]. Our results indicate that 1-MeA did not alter the phosphorylation status of Cx43. TPA was used as the positive control for hyperphosphorylation of Cx43, as indicated in a shift of the bands to higher molecular weights and the disappearance of the bottom band (unphosphorylated Cx43) ([Fig. 6C](#pone-0065150-g006){ref-type="fig"}). The lack of an effect on the phosphorylation of Cx43 by 1-MeA persisted after the activation of ERK1/2 and p38, similar to findings for 1-MeA treated rat liver cells [@pone.0065150-Upham2], [@pone.0065150-Rummel1] and p38 [@pone.0065150-Upham2]. Although Cx43 has consensus sequences for MAPKs [@pone.0065150-Lampe1], [@pone.0065150-WarnCramer1], these results indicate that other signaling factors, which were not activated in response to 1-MeA, are also required to phosphorylate Cx43. The phosphorylation of Cx43 by TPA is known to be dependent on protein kinase C and ERK1/2 [@pone.0065150-Rivedal1]. Alternatively, our results did show a decrease in all Cx43 bands that was consistent with our immunostaining experiments in which Cx43 localized to the cytoplasm, and displayed an overall decrease to near disappearance over our time course ([Fig. 7](#pone-0065150-g007){ref-type="fig"}).

PAHs {#s4b}
----

The structural differences between 1- and 2-MeA while minor in appearance, elicit completely different responses in the C10 cells due to the lack of a bay-like region in the 2-MeA structure compared to the 1-MeA structure. Similar differences were observed in other cell types, such as liver and pancreas [@pone.0065150-Upham2], [@pone.0065150-Tai1], thus these structural differences are not unique to lung.

Doses for these studies were chosen based on several studies demonstrating levels of LMW PAHs in sidestream smoke (ETS) were\>mainstream smoke (3186--5695 ng/cigarette) [@pone.0065150-Lee1], [@pone.0065150-Moir1]. At the low end of the range, 20 cigarettes/pack×3186 ng/cigarette×7d/wk = ∼ 0.45 mg/wk for the PAH mixture released as ETS. Our dose range is 0.03--0.04 mg/study per individual PAH, however, doses for future studies in mixtures will likely be lower, due to contributing effects [@pone.0065150-Ghoshal1]. These doses and PAHs were chosen to identify any differences in the phenotypes assessed between an active and inactive isomer, however, we are typically exposed to mixtures of multiple PAHs and not single PAHs. For example, coal tar pitch contains many PAHs [@pone.0065150-Services1], both LWM, such as methylanthracenes, and high MW PAHs, and recently was shown to induce promoting characteristics in lung cells [@pone.0065150-Feng1]. Furthermore, a mixture of PAHs commonly found in coal tar and creosote products demonstrated that dysregulation of GJIC by these PAHs were additive [@pone.0065150-Ghoshal1], thus there is a definite cumulative effect by many of the PAHs indicating that doses should be based on total PAH content.

MAPK Activation and Gap Junctions {#s4c}
---------------------------------

TPA, a classic tumor promoter in most cell types, dysregulates gap junctions through several mechanisms, including MAPKs (P38 and ERK1/2) via the activation of PKC [@pone.0065150-Rivedal1], [@pone.0065150-Pahujaa1], [@pone.0065150-Woodruff1]. Thus, some MAPK pathways are known to mediate the regulation of GJIC in several cell types [@pone.0065150-Rivedal1], [@pone.0065150-Yang1]. ERK1/2 also dysregulates gap junctions in other classic non-genotoxic carcinogen models, such as perfluoroalkanoates [@pone.0065150-Upham5]. However, the activation of ERK1/2 by 1-MeA was not involved in 1-MeA-induced dysregulation of GJIC in the lung cells used in this study, while P38 was involved. This suggests that ERK1/2 is independent of GJIC dysregulation, but is still activated by treatment with 1-MeA, while P38 is linked to GJIC shown by return of normal GJIC by inhibition of P38. Activation of P38 and ERK1/2 by 1-MeA is most likely through an indirect mechanism, eg. activation of receptors or G-proteins.

Gap Junction and MAPK Involvement in Regulating the Pulmonary Microenvironment {#s4d}
------------------------------------------------------------------------------

In most lung diseases, the pulmonary microenvironment is critical in regulating the inflammation and adverse effects that occur, such as fibrosis and carcinogenesis. Inflammation is an important element of tumorigenesis, at all stages, and is typically considered downstream of earlier triggering events, such as dysregulation of gap junctions and activation of MAPKs [@pone.0065150-Bauer2], [@pone.0065150-Cohen1], [@pone.0065150-Wu1].

P38 can induce Mcp-1 (Ccl2) in endothelial cells [@pone.0065150-Marin1], [@pone.0065150-Sung1], and induce other chemokines, such as IL-8, in lung epithelial cells [@pone.0065150-Schmeck1]. Cx43 decreased Mcp-1 expression in glioblastoma cells which lead to decreased proliferation, suggesting that a reduction in gap junction function lead to increased Mcp-1 [@pone.0065150-Huang1]. Ccl2 (Mcp-1) is routinely used as a marker in our *in vivo* promotion models, such as BHT and vanadium pentoxide (V~2~O~5~) [@pone.0065150-Rondini1], [@pone.0065150-Bauer4], because it is secreted by the pulmonary epithelial cells as a chemoattractant for both macrophages and lymphoctyes into the lung. Macrophage infiltration plays a pivotal role during promotion in these *in vivo* models and an *in vivo* pilot study using fluoranthene, another LMW PAH, demonstrated increased numbers of bronchoalveolar lavage macrophages in the lungs compared to controls (unpublished data, A.K. Bauer). V~2~O~5~-induced promotion also leads to increases in both ERK1/2 and P38 MAPK activation [@pone.0065150-Rondini1]. Thus, in our *in vitro* model, we show that *Mcp-1* is increased following MAPK activation (P38 and ERK1/2), and gap junction dysregulation, all evidence for 1-MeA's potential to contribute to the early signaling events involved in promoting lung cancer.

P38 is also considered the major MAPK involved in TNF-induction [@pone.0065150-Brook1], [@pone.0065150-Lee2]. Interestingly, TNF can also induce MAPK [@pone.0065150-Kim1], particularly P38, thus, a positive feed-forward mechanism may be involved in regulating this pathway. In addition, TNF can inhibit gap junctions in fibroblasts [@pone.0065150-Ito1] and repress Cx43 expression in keratinocytes [@pone.0065150-Tacheau1], thus supporting a possible link between pro-inflammatory cytokine expression and regulation of gap junctions.

In rat liver cells (WB F344) and human coronary artery endothelial cells, arachidonic acid (AA) is released in response to 1-MeA, but not 2-MeA [@pone.0065150-Upham2], [@pone.0065150-Tithof1]. Since Cox-2 is downstream of AA and cytosolic phospholipase A~2~ (cPLA~2~) [@pone.0065150-Bauer2], we determined the possible involvement of the Cox-2 pathway in our model. Prostaglandin E2 (PGE~2~) and prostaglandin I~2~ (PGI~2~) production, both downstream of Cox-2, are ERK1/2-dependent in response to TNF and interferon (IFN)γ stimulation in C10 cells as well as nitric oxide production and inducible nitric oxide synthase (iNOS) expression [@pone.0065150-DwyerNield1], [@pone.0065150-Rice1]. Preliminary data from our lab demonstrated that both p38 and ERK1/2 regulate Cox-2 gene expression in 1-MeA treated C10 cells (data not shown).

Conclusion {#s4e}
----------

Although the most abundant PAHs in the environment are the LMW PAHs, research on PAHs has focused primarily on the mutagenic and DNA damaging properties of the higher molecular weight compounds, however, evidence supports the LMW PAHs ability to induce molecular events relevant to lung injury, inflammation, and tumor promotion. We previously reported the effects of 41 different PAHs on GJIC in rat liver cell lines [@pone.0065150-Blaha1], [@pone.0065150-Weis1], [@pone.0065150-Ghoshal1], [@pone.0065150-Upham6] where most of these PAHs, including the high molecular weight PAHs, dysregulated GJIC with varying potencies [@pone.0065150-Blaha1], [@pone.0065150-Weis1]. However, the potencies of the LMW PAHs (4 rings or less) tended to be much stronger if they contained a bay or bay-like region [@pone.0065150-Upham1], [@pone.0065150-Blaha1], [@pone.0065150-Weis1].

Our results extend this research into a lung derived cell model system in which the PAH containing a bay-like structure was biologically active and the PAH lacking these structures was inactive, consistent with the liver model cell systems. Considering that the lung is the major organ of exposure to PAHs in the environment, these novel results suggest that the LMW, non-genotoxic PAHs could contribute to the lung injury and promotion process, thus posing a potential human health risk as well as linking LMW PAH-induced effects with proinflammatory responses, which was also dependent on the PAH possessing a bay-like structure. The role of inflammation in all stages of cancer, fibrosis, COPD, and many other pulmonary diseases further demonstrates the importance of this link between PAH exposure, early signaling and inflammatory mediator involvement [@pone.0065150-Allavena1]--[@pone.0065150-VanLaere1].

Collectively, this study provides the first assessment of the effects of these LMW PAHs on pulmonary cells that may lead to predictive outcomes for future identification of complex mixture effects, as well as identify novel targets for potential biomarkers, develop innovative chemopreventive strategies, and impact future risk assessment for these PAHs in lung and other cancers, such as liver, pancreas, and breast.

Supporting Information {#s5}
======================

###### 

**pERK1/2 at several doses of 1-MeA demonstrating increased ERK1/2 activation.** C10 cells were exposed to 25 and 50 µM 1-MeA for 2 h and compared to DMSO vehicle control treated cells (0 µM). Densitometry of the immunoblot is presented with mean ± SEM. \*P\<0.05 for 1-MeA treated cells compared to DMSO alone.

(TIF)

###### 

Click here for additional data file.

###### 

**Confirmation of inhibition of p38 and ERK1/2 activity following inhibitor incubation using immunoblots.** (A) A MAPKAPK-2 immunoblot in C10 cells demonstrating inhibition of phosphorylation of MAPKAPK-2, a known substrate of p38, compare lane 3 to lane 5 and 6. Lane 1, control, acetonitrile; lane 2, control+DMSO; lane 3, 1-MeA (75 µM); lane 4, control+SB203580 inhibitor (5 µM); lane 5, SB203580 (5 µM) inhibitor +1-MeA; lane 6, SB203580 (2.5 µM) inhibitor +1-MeA. Total MAPKAPK-2 is seen below the phosphorylated immunoblot demonstrating equal amounts of total in each sample. (B) pERK1/2 immunoblot following treatment with FR180204 (5 µM) or U0126 (20 µM) prior to treatment with 75 µM 1-MeA demonstrating inhibition of ERK phosphorylation in lanes 5 and 6 compared to 3. Lane 1, control, acetonitrile; lane 2, control+DMSO; lane 3, 1-MeA (75 µM); lane 4, control+FR180204 (5 µM); lane 5 FR180204 (5 µM) +1-MeA; lane 6, U0126 (20 µM) +1-MeA.

(TIF)

###### 

Click here for additional data file.
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